Bamlanivimab
Bamlanivimab (pronounced bam-lan-iv-im-ab) is a monoclonal antibody developed for the treatment of mild to moderate COVID-19 in adults and pediatric patients. It is specifically designed to block the virus' attachment and entry into human cells.
Etymology
The name "Bamlanivimab" is derived from the following components: "bam" from the company name BioNTech, "lan" for the targeted species (human), "vi" for the disease targeted (virus), "mab" for the product class (monoclonal antibody).
Usage
Bamlanivimab is used in patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. It is administered as a single dose intravenously.
Mechanism of Action
Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody that binds to the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus.
Related Terms
See Also
External links
- Medical encyclopedia article on Bamlanivimab
- Wikipedia's article - Bamlanivimab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski